

How can we protect vulnerable patients and the wider community?



Effective, timely RTI* diagnostics

*Respiratory tract infections

When time is critical and symptoms non-specific, **how do you differentiate respiratory viruses?**

30 people

are diagnosed with **tuberculosis** every hour in Europe.¹

1 billion

estimated cases of seasonal **influenza** are reported every year.²

COVID-19

presents similar symptoms to other viral respiratory infections like the flu.³

RTIs are highly transmissible and in a seasonal or **pandemic infection climate**, your lab may face unprecedented volumes of testing that can impact workflow efficiency. Diagnosing RTIs is already challenging, and an untimely diagnosis can result in greater transmission and can further exacerbate **antimicrobial resistance** for Tuberculosis.⁴

You need **accurate, rapid diagnostic solutions** with a flexible range of assays and sampling options to help ensure thorough, targeted results that curb the spread of pathogens and optimise your laboratory workflow. Implementing molecular diagnostic solutions may result in a low likelihood of **false positive and false negative results**.⁵

What would infection management processes look like if you could provide...



PCR test results in:

- **2 hours** for SARS-CoV-2 and Flu?
- **4 hours** for MDR-TB?



Rapid identification

of virus variants and RIF / INH resistance for Tuberculosis?



Flexibility for off-hour

testing with a fully automated platform to help address high testing volume?



1.5 minutes of hands-on

time per specimen?

Targeted, real-time PCR assays on the **BD MAX™ System** can simultaneously detect and differentiate respiratory viruses and their variants to help enable a holistic response to COVID-19 and RTIs altogether. Your lab will benefit from:

- High sensitivity and specificity for targeted detection
- Timely results for rapid patient management
- Detection of TB and MDR-TB from patients suspected of Tuberculosis infection

Benefit from flexible RTI testing options

BD SARS/Flu for BD MAX™ System

Co-test for SARS-CoV-2 (2 targets) and Flu A/ Flu B

Cat: 445011

VIASURE SARS-CoV-2, Flu (A+B) & RSV Kit

Deliver 4 results in one test!

Cat: 444217

VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Kit or BD SARS-CoV-2 reagents for BD MAX™ System

SARS-CoV-2 detection with 2 targets on N gene, remaining efficient for the detection of variants

Cat: 444215 and 445003-01

VIASURE Flu A, Flu B & RSV Kit

Flexible testing for Flu A, Flu B and RSV when needed

Cat: 444200

VIASURE SARS-CoV-2 Variant & Variant II Real Time PCR Kits

Identification and differentiation of concerned variants: Alpha, Beta, Gamma and Delta

Cat: 444216 and 444218

VIASURE Pneumocystis Real Time PCR Kit

Test for *Pneumocystis jirovecii* alone or as a second master mix with other respiratory assays from the Viasure line.

Cat: 444207

NEW

BD MAX™ MDR-TB and BD MAX™ STR

- Integrated molecular assay for the **detection of TB complex and mutations** associated with **RIF and INH resistances**
- Supported by the World Health Organization.

Cat: 443878 and 443806

You can choose from nasopharyngeal, nasal, oropharyngeal and saliva samples for maximum flexibility in SARS-CoV-2 testing.

BD MAX™ System – Fully integrated, automated real-time PCR platform with the possibility of running multiple assays simultaneously.*



Snap

Assemble unitised reagent strips with ready-to-use reagents.



Load

Load Sample Buffer Tubes, Racks and PCR Cartridges.



Go

Come back in an average of 2.5 hours for results.**

Discover our full assay portfolio and the BD MAX™ System



advancing-diagnostics.eu



advancingdiagnostics@bd.com

1. European Centre for Disease Prevention and Control. *Every hour 30 people are diagnosed with tuberculosis in the European Region. It's time to make TB a disease of the past*, 2019. Published March 19, 2019. Accessed January 19, 2022 at <https://www.ecdc.europa.eu/en/news-events/every-hour-30-people-are-diagnosed-tuberculosis-european-region-its-time-make-tb>. 2. World Health Organization. *8 Things to know about pandemic influenza*. Available at: <https://www.who.int/news-room/feature-stories/detail/8-things-to-know-about-pandemic-influenza>. Accessed January 2022. 3. Centers for Disease Control and Prevention. *Similarities and Differences between Flu and COVID-19*. Published on November 23, 2021. Accessed on January 2022 at <https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm>. 4. Olson G, Nathavitharana R, Lederer P. Diagnostic Delays and Treatment Implications for Patients with Isoniazid-Resistant Tuberculosis: A Case Report and Review of the Literature. *Open Forum Infect Dis*. 2019 May 14;6(6):ofz222. doi: 10.1093/ofid/ofz222. 5. Centers for Disease Control and Prevention. *Information on Rapid Molecular Assays, RT-PCR, and other Molecular Assays for Diagnosis of Influenza Virus Infection*. Available at: <https://www.cdc.gov/flu/professionals/diagnosis/molecular-assays.htm>. Accessed January 2022.

*BD assays are run & rack compatible – Only MDR-TB and GBS are not run and rack compatible / Vaginal Panel and open systems' assays are only run compatible

**Time to result is assay dependent. 4 hours for BD MAX™ MDR-TB assay.